At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.

Journal: Journal of affective disorders

PMID: 38810787

Abstract

BACKGROUND: Improving safe and effective access to ketamine therapy is of high priority given the growing burden of mental illness. Telehealth-supported administration of sublingual ketamine is being explored toward this goal.

Authors

David S Mathai

The Johns Hopkins University School of Medicine, Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, United States of America; Sattva Medicine - Psychiatry/Psychotherapy Practice, Miami, FL, United States of America.
Thomas D Hull

Talkspace, New York, NY, 10025, USA.
Leonardo Vando

Mindbloom, Orlando, FL, United States of America.
Matteo Malgaroli

Department of Psychiatry, New York University, Grossman School of Medicine, New York, NY, 10016, USA. matteo.malgaroli@nyulangone.org.

Keywords

Adult Antidepressive Agents Depression Depressive Disorder, Major Female Humans Ketamine Longitudinal Studies Machine Learning Male Middle Aged Telemedicine Treatment Outcome

External Resources

View on PubMed Access via DOI PubMed (38810787)

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals